A Look at Novel Approaches in Bone Mets

Article

Although the use of bisphosphonates is a well-established form of supportive care treatment for bone metastasis, complications arising from long-term use require schedule optimization and a search for alternative strategies.

Although the use of bisphosphonates is a well-established form of supportive care treatment for bone metastasis, complications arising from long-term use require schedule optimization and a search for alternative strategies. A recent study (Clin Cancer Res 2010 Aug 3) from the Massachusetts General Hospital Cancer Center, looked at studies optimizing bisphosphonate use and recent clinical data on denosumab in the treatment of bone disease. The study also provided insight into the preclinical rationale and clinical assessment of novel antiresorptive and anabolic bone-targeted agents.

Details available at:Novel Bone-Targeted Strategies in OncologyRelated content:Denosumab protects bones better than zoledronic acid in metastatic diseaseThe Role of Bisphosphonates in the Adjuvant Setting for Breast Cancer

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content